Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05211284 · ClinicalTrials.gov registry record · Phase 2
Saroglitazar Magnesium 4 mg for Nonalcoholic Fatty Liver Disease (NAFLD) in People Living With HIV in the US
A Phase 2 study, sponsored by Zydus Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT05211284 is a Phase 2 study that was terminated before completion, run by Zydus Therapeutics. The registered enrollment target is 4 participants.
The verdict
NCT05211284, a Phase 2 study, was terminated before completion, sponsored by Zydus Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
Saroglitazar Magnesium 4 mg for NAFLD in People Living with HIV in the US
Interventions
- DRUG Placebo
- DRUG Saroglitazar Magnesium 4 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2022-12-08 |
| Est. Completion | 2023-10-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05211284
The ClinicalTrials.gov registry entry for NCT05211284 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Zydus Therapeutics, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05211284 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05211284 about?
NCT05211284 is a clinical study titled "Saroglitazar Magnesium 4 mg for Nonalcoholic Fatty Liver Disease (NAFLD) in People Living With HIV in the US". Saroglitazar Magnesium 4 mg for NAFLD in People Living with HIV in the US
What is the current status of trial NCT05211284?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2022-12-08. Estimated completion is 2023-10-02.
What interventions are being tested in trial NCT05211284?
The interventions under investigation include: Placebo (DRUG), Saroglitazar Magnesium 4 mg (DRUG).
Who is sponsoring clinical trial NCT05211284?
This trial is sponsored by Zydus Therapeutics, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.